293 related articles for article (PubMed ID: 15044616)
1. Potent cyclic antagonists of the complement C5a receptor on human polymorphonuclear leukocytes. Relationships between structures and activity.
March DR; Proctor LM; Stoermer MJ; Sbaglia R; Abbenante G; Reid RC; Woodruff TM; Wadi K; Paczkowski N; Tyndall JD; Taylor SM; Fairlie DP
Mol Pharmacol; 2004 Apr; 65(4):868-79. PubMed ID: 15044616
[TBL] [Abstract][Full Text] [Related]
2. Small molecular probes for G-protein-coupled C5a receptors: conformationally constrained antagonists derived from the C terminus of the human plasma protein C5a.
Wong AK; Finch AM; Pierens GK; Craik DJ; Taylor SM; Fairlie DP
J Med Chem; 1998 Aug; 41(18):3417-25. PubMed ID: 9719594
[TBL] [Abstract][Full Text] [Related]
3. Low-molecular-weight peptidic and cyclic antagonists of the receptor for the complement factor C5a.
Finch AM; Wong AK; Paczkowski NJ; Wadi SK; Craik DJ; Fairlie DP; Taylor SM
J Med Chem; 1999 Jun; 42(11):1965-74. PubMed ID: 10354404
[TBL] [Abstract][Full Text] [Related]
4. Biologically active conformer of the effector region of human C5a and modulatory effects of N-terminal receptor binding determinants on activity.
Finch AM; Vogen SM; Sherman SA; Kirnarsky L; Taylor SM; Sanderson SD
J Med Chem; 1997 Mar; 40(6):877-84. PubMed ID: 9083476
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological characterization of antagonists of the C5a receptor.
Paczkowski NJ; Finch AM; Whitmore JB; Short AJ; Wong AK; Monk PN; Cain SA; Fairlie DP; Taylor SM
Br J Pharmacol; 1999 Dec; 128(7):1461-6. PubMed ID: 10602324
[TBL] [Abstract][Full Text] [Related]
6. The C terminus of the human C5a receptor (CD88) is required for normal ligand-dependent receptor internalization.
Bock D; Martin U; Gärtner S; Rheinheimer C; Raffetseder U; Arseniev L; Barker MD; Monk PN; Bautsch W; Köhl J; Klos A
Eur J Immunol; 1997 Jun; 27(6):1522-9. PubMed ID: 9209506
[TBL] [Abstract][Full Text] [Related]
7. Direct binding of a fragment of the Wiskott-Aldrich syndrome protein to the C-terminal end of the anaphylatoxin C5a receptor.
Tardif M; Brouchon L; Rabiet MJ; Boulay F
Biochem J; 2003 Jun; 372(Pt 2):453-63. PubMed ID: 12600272
[TBL] [Abstract][Full Text] [Related]
8. Selection of a C5a receptor antagonist from phage libraries attenuating the inflammatory response in immune complex disease and ischemia/reperfusion injury.
Heller T; Hennecke M; Baumann U; Gessner JE; zu Vilsendorf AM; Baensch M; Boulay F; Kola A; Klos A; Bautsch W; Köhl J
J Immunol; 1999 Jul; 163(2):985-94. PubMed ID: 10395696
[TBL] [Abstract][Full Text] [Related]
9. Selective hexapeptide agonists and antagonists for human complement C3a receptor.
Scully CC; Blakeney JS; Singh R; Hoang HN; Abbenante G; Reid RC; Fairlie DP
J Med Chem; 2010 Jul; 53(13):4938-48. PubMed ID: 20527893
[TBL] [Abstract][Full Text] [Related]
10. Novel C5a receptor antagonists regulate neutrophil functions in vitro and in vivo.
Pellas TC; Boyar W; van Oostrum J; Wasvary J; Fryer LR; Pastor G; Sills M; Braunwalder A; Yarwood DR; Kramer R; Kimble E; Hadala J; Haston W; Moreira-Ludewig R; Uziel-Fusi S; Peters P; Bill K; Wennogle LP
J Immunol; 1998 Jun; 160(11):5616-21. PubMed ID: 9605167
[TBL] [Abstract][Full Text] [Related]
11. Development of C5a receptor antagonists. Differential loss of functional responses.
Konteatis ZD; Siciliano SJ; Van Riper G; Molineaux CJ; Pandya S; Fischer P; Rosen H; Mumford RA; Springer MS
J Immunol; 1994 Nov; 153(9):4200-5. PubMed ID: 7930622
[TBL] [Abstract][Full Text] [Related]
12. Modeling molecular mechanisms of binding of the anaphylatoxin C5a to the C5a receptor.
Nikiforovich GV; Marshall GR; Baranski TJ
Biochemistry; 2008 Mar; 47(10):3117-30. PubMed ID: 18275159
[TBL] [Abstract][Full Text] [Related]
13. Disulfide trapping to localize small-molecule agonists and antagonists for a G protein-coupled receptor.
Buck E; Wells JA
Proc Natl Acad Sci U S A; 2005 Feb; 102(8):2719-24. PubMed ID: 15710877
[TBL] [Abstract][Full Text] [Related]
14. Antagonistic peptides against human anaphylatoxin C5a.
Kaneko Y; Okada N; Baranyi L; Azuma T; Okada H
Immunology; 1995 Sep; 86(1):149-54. PubMed ID: 7590876
[TBL] [Abstract][Full Text] [Related]
15. Probing the human receptor for C5a anaphylatoxin with site-directed antibodies. Identification of a potential ligand binding site on the NH2-terminal domain.
Oppermann M; Raedt U; Hebell T; Schmidt B; Zimmermann B; Götze O
J Immunol; 1993 Oct; 151(7):3785-94. PubMed ID: 8376805
[TBL] [Abstract][Full Text] [Related]
16. Plasma clearance of the human C5a anaphylatoxin by binding to leucocyte C5a receptors.
Oppermann M; Götze O
Immunology; 1994 Aug; 82(4):516-21. PubMed ID: 7835913
[TBL] [Abstract][Full Text] [Related]
17. Identification of putative agouti-related protein(87-132)-melanocortin-4 receptor interactions by homology molecular modeling and validation using chimeric peptide ligands.
Wilczynski A; Wang XS; Joseph CG; Xiang Z; Bauzo RM; Scott JW; Sorensen NB; Shaw AM; Millard WJ; Richards NG; Haskell-Luevano C
J Med Chem; 2004 Apr; 47(9):2194-207. PubMed ID: 15084118
[TBL] [Abstract][Full Text] [Related]
18. Anti-C5a receptor antibodies. Characterization of neutralizing antibodies specific for a peptide, C5aR-(9-29), derived from the predicted amino-terminal sequence of the human C5a receptor.
Morgan EL; Ember JA; Sanderson SD; Scholz W; Buchner R; Ye RD; Hugli TE
J Immunol; 1993 Jul; 151(1):377-88. PubMed ID: 8326131
[TBL] [Abstract][Full Text] [Related]
19. Solution structure of a unique C5a semi-synthetic antagonist: implications in receptor binding.
Zhang X; Boyar W; Galakatos N; Gonnella NC
Protein Sci; 1997 Jan; 6(1):65-72. PubMed ID: 9007977
[TBL] [Abstract][Full Text] [Related]
20. Antiarthritic activity of an orally active C5a receptor antagonist against antigen-induced monarticular arthritis in the rat.
Woodruff TM; Strachan AJ; Dryburgh N; Shiels IA; Reid RC; Fairlie DP; Taylor SM
Arthritis Rheum; 2002 Sep; 46(9):2476-85. PubMed ID: 12355496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
